РЕКОМЕНДАЦИИ ЕВРОПЕЙСКОГО ОБЩЕСТВА КАРДИОЛОГОВ И ЕВРОПЕЙСКОГО ОБЩЕСТВА АТЕРОСКЛЕРОЗА ПО ЛЕЧЕНИЮ ДИСЛИПИДЕМИЙ
Zeljko Reiner, David Wood(Valve (United States)), Richard Hobbs(University of Oxford), Olov Wiklund(Translational Therapeutics (United States)), John Kjekshus(Nuffield Health), Stefan Agewall(Karolinska Institutet), Robert F. Storey(University of Sheffield), Ian Graham(Ottawa Hospital), Julian Halcox(Swansea University), M. John Chapman(University of Cambridge), Paul N. Durrington(University of Manchester), Pasquale Perrone Filardi(Fondazione Toscana Gabriele Monasterio), Alberico L. Catapano(University of Milan), Gabriele Riccardi(University of Milan), Eduardo Alegría(Policlínica Gipuzkoa), Marja‐Riitta Taskinen(Hospital District of Helsinki and Uusimaa), Serap Erdine(University of Milan)
Cited by 0
Related Papers
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.4k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k